We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
-0.44%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$256M
AUM Growth
-$27.3M
Cap. Flow
-$13M
Cap. Flow %
-5.06%
Top 10 Hldgs %
49.1%
Holding
75
New
10
Increased
14
Reduced
12
Closed
12

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$9.88M
2
SHPG
Shire pic
SHPG
+$9.33M
3
ARRY
Array Biopharma Inc
ARRY
+$5.99M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$3.81M
5
SAGE
Sage Therapeutics
SAGE
+$3.23M

Top Sells

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$12.6M
2
ENTL
Entellus Medical, Inc. Common Stock
ENTL
+$8.32M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$8.06M
4
AMGN icon
Amgen
AMGN
+$6.28M
5
BIIB icon
Biogen
BIIB
+$6.02M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGYP
26
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$2.73M 1.06%
1,505,809
+5
+0% +$11
PBYI icon
27
Puma Biotechnology
PBYI
$477M
$2.31M 0.9%
34,000
+22,000
+183% +$1.65M
SGEN
28
DELISTED
Seagen Inc. Common Stock
SGEN
$2.22M 0.87%
42,500
-15,000
-26% -$817K
AVXS
29
DELISTED
AveXis, Inc. Common Stock
AVXS
$2.1M 0.82%
17,000
– –
RARE icon
30
Ultragenyx Pharmaceutical
RARE
$2.59B
$2.09M 0.82%
+41,000
New +$2.06M
SRPT icon
31
Sarepta Therapeutics
SRPT
$2.28B
$2M 0.78%
27,000
– –
MTEM
32
DELISTED
Molecular Templates, Inc.
MTEM
$1.98M 0.77%
16,506
– –
CBAY
33
DELISTED
Cymabay Therapeutics
CBAY
$1.88M 0.74%
145,000
– –
AXGN icon
34
Axogen
AXGN
$2.78B
$1.82M 0.71%
+50,000
New +$1.53M
PEN icon
35
Penumbra
PEN
$12.6B
$1.62M 0.63%
+14,000
New +$1.45M
ONC
36
BeOne Medicines Ltd
ONC
$42.1B
$1.6M 0.62%
9,500
– –
DCPH
37
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$1.54M 0.6%
77,000
– –
ASXC
38
DELISTED
Asensus Surgical, Inc.
ASXC
$1.5M 0.59%
68,391
– –
XENT
39
DELISTED
Intersect ENT, Inc
XENT
$1.45M 0.57%
+37,000
New +$1.35M
KYNB
40
Kyntra Bio
KYNB
$32.4M
$1.45M 0.57%
1,256
– –
GMED icon
41
Globus Medical
GMED
$11.1B
$1.45M 0.56%
+29,000
New +$1.36M
MRUS
42
DELISTED
Merus
MRUS
$1.39M 0.54%
+75,060
New +$1.36M
PRTK
43
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$1.35M 0.53%
103,500
-150,000
-59% -$2.23M
RIGL icon
44
Rigel Pharmaceuticals
RIGL
$875M
$1.3M 0.51%
+37,000
New +$1.48M
OPTN
45
DELISTED
OptiNose
OPTN
$1.3M 0.51%
4,333
– –
TSRO
46
DELISTED
TESARO, Inc.
TSRO
$1.22M 0.47%
21,300
-56,000
-72% -$3.6M
VSTM icon
47
Verastem
VSTM
$668M
$1.19M 0.47%
+33,333
New +$1.29M
RSLS
48
DELISTED
ReShape Lifesciences Inc. Common Stock
RSLS
$1.14M 0.45%
375
– –
FSTX
49
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$1.09M 0.43%
18,250
– –
GWPH
50
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$1.08M 0.42%
9,600
– –
1
2
3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q1 2018 Portfolio in Review

As of Q1 2018, International Biotechnology Trust held 75 positions worth $256M, down 9.6% from $284M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

International Biotechnology Trust withdrew a net $13M in Q1 2018, closing 12 positions and reducing 12 holdings. Its most notable exit was Nektar Therapeutics, an estimated $12.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, International Biotechnology Trust opened a new position in Jazz Pharmaceuticals worth $2.87M.

  • International Biotechnology Trust's largest Q1 2018 buy was Jazz Pharmaceuticals: 19,000 shares worth $2.87M.
  • International Biotechnology Trust added most to Neurocrine Biosciences in Q1 2018, an estimated $9.88M increase.
  • International Biotechnology Trust's biggest Q1 2018 reduction was Acadia Pharmaceuticals, cutting an estimated $8.06M.
  • International Biotechnology Trust fully exited Nektar Therapeutics in Q1 2018, selling an estimated $12.6M.
  • International Biotechnology Trust's ten largest holdings make up 49% of its $256M portfolio in Q1 2018.
  • International Biotechnology Trust opened 10 new positions and closed 12 in Q1 2018.
  • International Biotechnology Trust's portfolio value fell 9.6% quarter-over-quarter to $256M.

Based on International Biotechnology Trust's 13F filing for Q1 2018, filed 15 May 2018.